Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: Humpty-Dumpty sat on a wall and had a great fall

September 6, 2018 5:28pm

I had stated in the pre-open, “I am ambivalent towards today’s upcoming session; although there are few highs with strength that need to be sold into, some lows that could go lower and few buys that need to be jumped-on!”

All the trading horses and all the retail and institutional men won’t put Humpty together again – for a while …

Pre-open indications: 4 HITs and 3 MISS

When is it wrong to be RIGHT in sector prognosis? Sangamo Therapeutics (SGMO -$1.50 or -10.31%) dived more while - CRISPR Therapeutics (CRSP -$3.57 or -6.68%), Editas Medicine (EDIT -$1.99 or -6.22%) and Intellia Therapeutics (NTLA -$2.99 or -9.95%) continued their decline!

Maybe because I’m NOT I-Bank fee driven!

Who is defining the metrics for individual investors? Your portfolio should be profiting from RMi’s analysis!

Henry’omics:

Sector equities fell on Thursday adding to yesterday’s losses – I have NOT seen this amount of decline in quite a while … fears of risk more than lingers.

Re the title, it’s more than a riddle - probably exploited, for misdirection, the fact that "humpty dumpty" was also eighteenth-century reduplicative slang for a short and clumsy person or maybe a sector that just fell-off the wall of worry!

As I had stated, “Political views are going to be the basis of the day; what do we believe about President Thump; tariffs; trade wars and is there a real and tangible basis for writing the “op-ed”? It will dominate the airways … and be the topic of more than many conversations taking the “notice” off the markets!”

From the pre-open newsletter: “as I asked, what’s next to buffet the sector after two trial misses, low volume and downside volatility … Understand three things; a dice toss doesn’t always roll a seven, investing is also a wager and there is a time to take money off the table after steep inclines and as hazards exist.”

Yet I will and can say – a bounce-back is coming …

Pre-open indications: 4 HITs and 3 MISS

bluebird bio (BLUE) closed down -$9.10 – miss;
BioLife Solutions (BLFS) closed down -$1.49 – miss;
Intellia Therapeutics (NTLA) closed down -$2.99 – hit;
Editas Medicine (EDIT) closed down -$1.99 – hit;
Solid Biosciences (SLDB) closed down -$4.32 – hit;
Verastem Oncology (VSTM) closed down -$0.45 – miss;
Vericel (VCEL) closed down -$0.80 – hit;

Of the 45 companies covered on Thursday; 39 downside equities finished in a range of -0.20% (SAGE) to -10.46% (BLCM) while 1 upside equity oscillated from +1.97% (BCLI) with 5 flat closes (PSTI, RENE.L, MESO, ADRO and BSTG).

Out and about:

Reiterating: CRISPR Therapeutics (CRSP +18.7%), Intellia Therapeutics (NTLA +16.2%) and Editas Medicine (EDIT +10.4%) were up in the month of August;

Validating MY thesis of being OVERBOUGHT:

Thursday’s session: CRISPR Therapeutics (CRSP -$3.57 or -6.69%), Editas Medicine (EDIT -$1.99 or -6.22%) and Intellia Therapeutics (NTLA -$2.99 or -9.95%) followed Sangamo Therapeutics (SGMO - $1.50 or -10.31%) in taking another dive!

Wednesday’s session: CRISPR Therapeutics (CRSP -$2.05 or -3.69%), Editas Medicine (EDIT -$0.80 or -2.44%) and Intellia Therapeutics (NTLA -$0.68 or -2.21%) joined SGMO in taking a dive!

Yesterday: CRISPR Therapeutics (CRSP -$2.56 or -4.61%), Editas Medicine (EDIT -$1.27 or -3.87%) and Intellia Therapeutics (NTLA -$0.56 or -1.81%) – check the daily ranges for the full effect!

Tuesday (9/4) CRISPR Therapeutics (CRSP -$1.17 or -2.06%), Editas Medicine (EDIT -$0.03 or -0.09%) and Intellia Therapeutics (NTLA -$0.19 or -0.61%) – check the daily ranges for the full effect!

I’ve MAINTAINED a TRADE on these OVERBOUGHT equities …

Daily analytics and metrics:

The Dow closed up +37.19 points or +0.14% to 26,012.18,
The S&P closed down -9.36 points or -0.32% to 2,979.28,
The NASDAQ closed down -69.64 points or -0.88% to 7,924.29

The advance/decline line scenario of 45 covered companies:

The open was negative with an A/DL of 18/20 and 7 flats;
The first hour increased its negativity with an A/DL of 10/30 and 5 flats;
The mid-day continued negative with an A/DL of 5/37 and 3 flats;
The close was negative with an A/DL of 1/39 and 5 flats;

Daily volume anomaly (increased volume versus 3 month average):

BSTG – volume was up and closed flat
BCLI – volume and pricing was up
AST – volume was up and pricing down
BOLD – volume was up and pricing was down
ADRO – volume was up and closed flat
BLCM –volume was up and pricing was down
BMRN – volume was up and pricing was down
SGMO – volume was up and pricing was down

Four (4) key metrics:

… The greatest volume to the downside: SGMO, HSGX, VSTM, VCEL and GBT

… Upside volume was weighted to: BCLI

… Leadership ($) to the downside: BLUE (-$9.10), ALNY (-$5.95), SLDB (-$4.32), CRSP (-$3.57) and RARE (-$3.25)

… Best moves ($) to the upside: BCLI (+$0.08)

The iShares NASDAQ Biotechnology (IBB) closed:

Thursday was down -1.78%
Wednesday was down -0.30%
Tuesday was down -0.97%
Monday was a holiday
Friday was up +0.16%
Last Thursday was up +0.39%

September sessions:

Thursday’s closed with 39 decliners, 1 advancer and 5 flats
Wednesday’s closed with 30 decliners, 12 advancers and 3 flats
Tuesday’s (9/4) closed with 22 decliners, 19 advancers and 4 flats

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.